SV

Street Verdict

Analyst Scorecard

A record of what Rahul Sharma said publicly, with the source. Not advice.

“Conditionally bullish on Glenmark Pharma, recommending a buy once it crosses the resistance area of 1975 (currently at 1962), with targets at 2050-2070. The risk-reward is favorable, and a stop loss can be placed at 1930.”

Rahul Sharma’s track record (trackable calls only): 34 graded calls · 95% CI 37–69%

Glenmark Pharmaceuticals LtdBullishCalled 11 Dec 2025Graded 02 Jan 2026
Verdict:HIT

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹2,050, as stated.

Window: 30 days, the default when no time frame is stated.

The target ₹2,050 was reached on a close. Hit.

The grader’s working: R4 TARGET_CALL: entered ₹1975 on 2025-12-12 (next trading session's close); target ₹2050 reached at close ₹2064.5 on 2026-01-02. Window 30 days — rule H2: a technical setup whose quote states no time frame is given 30 days.

How it played out

How this is worked out
Time to target
The target was reached on a close 14 trading sessions (21 calendar days) after the entry.
Worst close against it
The closing price went as far as 1.35% against the call before the target was reached, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Tracking Glenmark Pharmaceuticals Ltd since this call

1-year tracking window
Read the original articleSee Rahul Sharma’s full track record